Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Mirtazapine Treatment of Anxiety in Children and Adolescents With Pervasive Developmental Disorders

NCT01302964 is registered in ClinicalTrials.gov with Massachusetts General Hospital as lead sponsor.

NCT NCT01302964
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01302964 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Mirtazapine Treatment of Anxiety in Children and Adolescents With Pervasive Developmental Disorders
Lead sponsor
Massachusetts General Hospital
Phase
Phase 3
Overall status
Completed
Start date
August 31, 2010
Completion date
October 10, 2017
Enrollment
30 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

autism spectrum disorders